---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-061104"
form_type: "8-K"
ticker: "RANI"
cik: "0001856725"
company_name: "Rani Therapeutics Holdings, Inc."
filed_at: "2023-11-08T23:59:59+00:00"
generated_at: "2026-06-08T11:00:45.147555+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Rani Therapeutics Q3 net loss $18.3M, cash $60.5M, CEO salary cut to $100k, workforce reduced 25%

## Summary
- Net loss $18.3M in Q3 2023 vs $16.2M in Q3 2022; R&D spend $11.2M, cash burn extends runway into 2025.
- CEO Talat Imran salary reduced from $520k to $100k through 2024 or until $50M is raised.
- Strategic prioritization: discontinue RT-101, pause RT-105/RT-110, workforce cut ~25%.
- RT-102 Phase 2 starts year-end 2023; RT-111 Phase 1 topline expected Q1 2024; RaniPill HC Phase 1-ready 2H 2024.
- RaniPill HC achieved >90% drug delivery success in preclinical studies with adalimumab and interleukin.

## SEC filing metadata
- accession: 0000950170-23-061104
- form_type: 8-K
- ticker: RANI
- cik: 0001856725
- company_name: Rani Therapeutics Holdings, Inc.
- filed_at: 2023-11-08T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1856725/000095017023061104/0000950170-23-061104-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1856725/000095017023061104/rani-20231108.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-061104
- JSON: https://secwatch.observer/filing/0000950170-23-061104.json
- Plain text: https://secwatch.observer/filing/0000950170-23-061104.txt

## Key facts
- Earnings Releases
  Rani Therapeutics Holdings, Inc. reported financial results for the third quarter ended September 30, 2023.
  - Period: the third quarter ended September 30, 2023
  - Result: reported results
  source text: On November 8, 2023, Rani Therapeutics Holdings, Inc. (the “Company”) issued a press release providing a corporate update and announcing its financial results for the third quarter ended September 30, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1856725/000095017023061104/0000950170-23-061104-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.